Cargando…

Convalescent plasma in outpatients with COVID-19

Detalles Bibliográficos
Autores principales:	Focosi, Daniele, Casadevall, Arturo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828368/ https://www.ncbi.nlm.nih.gov/pubmed/35150608 http://dx.doi.org/10.1016/S2213-2600(22)00050-9

Ejemplares similares

High-Dose Convalescent Plasma for Treatment of Severe COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

Convalescent plasma for COVID-19. TSUNAMI is not the final word
por: Franchini, Massimo, et al.
Publicado: (2022)

On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy
por: Focosi, Daniele, et al.
Publicado: (2022)

WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients?
por: Franchini, Massimo, et al.
Publicado: (2023)

COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
por: Focosi, Daniele, et al.
Publicado: (2022)

Convalescent plasma in patients hospitalised with COVID-19
por: Liu, Sean T H, et al.
Publicado: (2021)

Convalescent plasma as a potential therapy for COVID-19
por: Chen, Long, et al.
Publicado: (2020)

Convalescent plasma for COVID-19 in oncohematological patients: a call for revision of the European Conference on Infections in Leukemia-9 (ECIL-9) guidelines
por: Focosi, Daniele, et al.
Publicado: (2023)

Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J, et al.
Publicado: (2022)

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis
por: Senefeld, Jonathon W., et al.
Publicado: (2023)

Convalescent plasma from people vaccinated after COVID-19 infection
por: Jabal, Kamal Abu, et al.
Publicado: (2021)

Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe
por: Focosi, Daniele, et al.
Publicado: (2022)

The art of the possible in approaching efficacy trials for COVID19 convalescent plasma
por: Focosi, Daniele, et al.
Publicado: (2021)

COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors
por: Focosi, Daniele, et al.
Publicado: (2021)

Use of convalescent plasma in the treatment of COVID-19
por: Joyner, Michael J., et al.
Publicado: (2023)

Convalescent Plasma Therapy for COVID-19: State of the Art
por: Focosi, Daniele, et al.
Publicado: (2020)

COVID-19 convalescent plasma transfusion
por: Langhi, Dante Mário, et al.
Publicado: (2020)

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J., et al.
Publicado: (2022)

COVID-19 Convalescent Plasma and Concomitant Therapies in PassITON
por: Casadevall, Arturo, et al.
Publicado: (2022)

Rethinking the role of COVID-19 convalescent plasma in the critically ill
por: Casadevall, Arturo, et al.
Publicado: (2023)

Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews
por: Franchini, Massimo, et al.
Publicado: (2021)

Early Outpatient Treatment for Covid-19 with Convalescent Plasma
por: Sullivan, David J., et al.
Publicado: (2022)

Convalescent plasma to deliver therapeutic antibodies against COVID-19
por: Senefeld, Jonathon W., et al.
Publicado: (2022)

COVID-19 Serology Data Provide Guidance for Future Deployments of Convalescent Plasma
por: Sullivan, David, et al.
Publicado: (2023)

The emergency use authorization for COVID‐19 convalescent plasma reduced mortality
por: Paneth, Nigel, et al.
Publicado: (2023)

Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency
por: Focosi, D., et al.
Publicado: (2021)

The Assessment of Convalescent Plasma Efficacy against COVID-19
por: Casadevall, Arturo, et al.
Publicado: (2020)

A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment
por: Focosi, Daniele, et al.
Publicado: (2022)

Is a single COVID-19 vaccine dose enough in convalescents ?
por: Focosi, Daniele, et al.
Publicado: (2021)

High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19
por: So-Osman, Cynthia, et al.
Publicado: (2022)

Implications of Coronavirus Disease 2019 (COVID-19) Antibody Dynamics for Immunity and Convalescent Plasma Therapy
por: Casadevall, Arturo, et al.
Publicado: (2020)

How do I implement an outpatient program for the administration of convalescent plasma for COVID‐19?
por: Bloch, Evan M., et al.
Publicado: (2022)

Early Convalescent Plasma for High-Risk Outpatients with Covid-19
por: Korley, Frederick K., et al.
Publicado: (2021)

Clinical and Virological Response to Convalescent Plasma in a Chronic Lymphocytic Leukemia Patient with COVID-19 Pneumonia
por: Belcari, Giovanni, et al.
Publicado: (2022)

What is the optimal usage of coronavirus disease 2019 convalescent plasma donations?
por: Focosi, Daniele, et al.
Publicado: (2021)

Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality
por: Casadevall, Arturo, et al.
Publicado: (2021)

Antibody Correlates of Protection for COVID-19 Convalescent Plasma Associated with Reduced Outpatient Hospitalizations
por: Park, Han-Sol, et al.
Publicado: (2023)

Absence of pathogenic viruses in COVID‐19 convalescent plasma
por: Kandathil, Abraham J., et al.
Publicado: (2022)

Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients—An Open-Label Phase II Clinical Trial
por: Grubovic Rastvorceva, Rada M., et al.
Publicado: (2022)

Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma
por: Sullivan, David J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8e3bft56km4jhol7t1ia7r8r73